|1.||McCreary, A C: 3 articles (09/2015 - 08/2010)|
|2.||Sumiyoshi, Tomiki: 3 articles (01/2013 - 03/2006)|
|3.||Wolf, William A: 3 articles (05/2007 - 07/2003)|
|4.||Varney, M A: 2 articles (09/2015 - 06/2015)|
|5.||Cenci, M A: 2 articles (09/2015 - 06/2015)|
|6.||Newman-Tancredi, A: 2 articles (09/2015 - 06/2015)|
|7.||Iderberg, H: 2 articles (09/2015 - 06/2015)|
|8.||Morimoto, Tomoki: 2 articles (04/2015 - 10/2013)|
|9.||Shimizu, Saki: 2 articles (04/2015 - 10/2013)|
|10.||Sobue, Akira: 2 articles (04/2015 - 10/2013)|
|1.||Migraine Disorders (Migraine)
06/01/1993 - "Further studies are cited to support two possible mechanisms of action for the efficacy of 5-HT1 agonists in treating migraine. "
09/01/2001 - "Safety and efficacy of PNU-142633, a selective 5-HT1D agonist, in patients with acute migraine."
01/01/1996 - "311C90, a novel 5-HT1D agonist drug, which is also highly effective in the acute treatment of migraine, acts not only at these sites, but, additionally within the brainstem, inhibiting trigemino-vascular activation centrally as well as peripherally. "
01/01/1996 - "The 5-HT1D agonist sumatriptan, which is highly effective in the acute treatment of migraine, inhibits trigemino-vascular activation in animals, although its actions are normally limited to peripheral components of the trigemino-vascular system. "
04/01/1997 - "The efficacy of BMS 180048, a 5-HT1 agonist in the acute treatment of a migraine headache, was evaluated in 216 patients. "
|2.||Cerebellar Ataxia (Dysmetria)
01/01/2005 - "Treatment of cerebellar ataxia with 5-HT1A agonist."
01/01/2004 - "In a double-blind randomized study, buspirone, a 5-HT1A agonist was active in cerebellar ataxia, but the effect is partial and not major. "
01/01/1997 - "To test further the serotonergic hypothesis of cerebellar ataxia, we administered buspirone, a 5-HT1A agonist usable in human medicine, in a randomized double blind drug placebo trial for 4 months. "
01/01/1997 - "Buspirone, a serotonergic 5-HT1A agonist, is active in cerebellar ataxia. "
01/01/2005 - "We recently reported preliminary evidence that tandospirone citrate (tandospirone), a 5-HT1A agonist, improved cerebellar ataxia in patients with Machado-Joseph disease (MJD). "
03/01/2002 - "5-HT1 agonists improve impaired gastric accommodation and symptoms in patients with functional dyspepsia. "
01/01/2002 - "5-HT1 agonists may play a role in treating functional dyspepsia, partly by improving impaired gastric accommodation to a meal. "
06/01/2009 - "A placebo-controlled trial of the 5-HT1A agonist R-137696 on symptoms, visceral hypersensitivity and on impaired accommodation in functional dyspepsia."
11/01/2009 - "Efficacy of the 5-HT1A agonist tandospirone citrate in improving symptoms of patients with functional dyspepsia: a randomized controlled trial."
02/01/2013 - "The effects of antidepressants on the gastrointestinal tract may contribute to their potential efficacy in functional dyspepsia and irritable bowel syndrome; buspirone, a prototype 5-HT1A agonist, enhances gastric accommodation and reduces postprandial symptoms in response to a challenge meal. "
|4.||Anxiety Disorders (Anxiety Disorder)
06/01/2006 - "We report the discovery of a novel, potent, and selective amidosulfonamide nonazapirone 5-HT1A agonist for the treatment of anxiety and depression, which is now in Phase III clinical trials for generalized anxiety disorder (GAD). "
09/01/2005 - "To examine the efficacy of buspirone, a 5-HT1A agonist, for migraine combined with anxiety disorder. "
01/01/2005 - "Although the picture is far from complete yet--partly due to the large number of serotonin (5-HT) receptors and the often-disparate effects of receptor agonists and antagonists in animal models of anxiety--SSRIs and the 5-HT1A agonist buspirone have now earned their place in the treatment of anxiety disorders. "
12/01/2003 - "Provided these results can be extrapolated to humans, the efficacy of EMD 128130 in relieving the haloperidol-induced muscle rigidity supports the concept that novel antipsychotics with 5-HT1A agonist and dopamine D2 antagonist activities should have a favourable extrapyramidal side-effect profile."
12/01/2003 - "The aim of the present study was to find out whether (+/-)-8-hydroxy-2(di-n-propylamino)tetralin (8-OH-DPAT), a prototypical 5-HT1A agonist, and (R)-(-)-2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane HCl (EMD 128130), a compound with serotonin 5-HT1A-agonist and dopamine D2-like antagonist properties, are able to attenuate the haloperidol-induced (1 mg/kg) muscle rigidity in rats. "
|3.||Citric Acid (Citrate)
|6.||Antipsychotic Agents (Antipsychotics)